Literature DB >> 8458607

Urinary free cortisol in the assessment of hydrocortisone replacement therapy.

P J Trainer1, K C McHardy, R D Harvey, I W Reid.   

Abstract

Glucocorticoid replacement therapy should be tailored to individual patients' requirements to avoid the risks of over and under treatment. Serum and urinary free cortisol profiles over 24 hours were compared as a means of assessing replacement therapy in nine patients on long-term twice daily hydrocortisone. Both indices varied in relationship to the timing and dose of hydrocortisone and there was a close correlation between individual measurements of serum and urinary free cortisol (r = 0.885, p < 0.0001). Collection of urine samples offers certain advantages over repeated serum sampling and urinary free cortisol measurement may have a role in the assessment of hydrocortisone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458607     DOI: 10.1055/s-2007-1002056

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism.

Authors:  L Barbetta; C Dall'Asta; T Re; R Libè; E Costa; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2005 Jul-Aug       Impact factor: 4.256

Review 2.  Diabetes in Cushing Disease.

Authors:  G Mazziotti; A M Formenti; S Frara; F Maffezzoni; M Doga; A Giustina
Journal:  Curr Diab Rep       Date:  2017-05       Impact factor: 4.810

3.  Evaluation of two replacement regimens in primary adrenal insufficiency patients. effect on clinical symptoms, health-related quality of life and biochemical parameters.

Authors:  N Alonso; M L Granada; A Lucas; I Salinas; J Reverter; A Oriol; A Sanmarti
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

4.  Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses.

Authors:  S Laureti; A Falorni; F Santeusanio
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.